Attenuation of urokinase activity during experimental ischaemia protects the cerebral barrier from damage through regulation of matrix metalloproteinase-2 and NAD(P)H oxidase

European Journal of Neuroscience

Volumn 39, Issue 12, 2014, Pages 2119-2128

  Rakkar, Kamini ^a   Srivastava, Kirtiman ^a   Bayraktutan, Ulvi ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Blood brain barrier; Matrix metalloproteinase; P22 phox; Reperfusion injury; Superoxide anion

Indexed keywords

ALBUMIN; COMPLEMENTARY DNA; GELATINASE A; GLUCOSE; MEMBRANE PROTEIN; OXYGEN; PLASMIN; PLASMINOGEN; PROTEIN P22 PHOX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; GELATINASE B; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN;

ARTICLE; ASTROCYTE; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN ISCHEMIA; CELL HYPOXIA; CELL LEVEL; CONTROLLED STUDY; ELECTROPORATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROVASCULAR ENDOTHELIAL CELL; NERVOUS SYSTEM PARAMETERS; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION; SIGNAL TRANSDUCTION; TRANSENDOTHELIAL ELECTRICAL RESISTANCE; ANOXIA; ANTAGONISTS AND INHIBITORS; BRAIN; CAPILLARY PERMEABILITY; CELL CULTURE; COCULTURE; DEFICIENCY; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; IMPEDANCE; ISCHEMIA; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANOXIA; ASTROCYTES; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CELLS, CULTURED; COCULTURE TECHNIQUES; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; GLUCOSE; HUMANS; ISCHEMIA; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NADPH OXIDASE; SUPEROXIDES; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84902553814     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/ejn.12552     Document Type: Article

References (46)

1. Ahn, M.Y., Zhang, Z.G., Tsang, W. & Chopp, M. (1999) Endogenous plasminogen activator expression after embolic focal cerebral ischemia in mice. Brain Res., 837, 169-176.
2. Allen, C.L. & Bayraktutan, U. (2009a) Antioxidants attenuate hyperglycaemia-mediated brain endothelial cell dysfunction and blood-brain barrier hyperpermeability. Diabetes Obes. Metab., 11, 480-490.
3. Allen, C.L. & Bayraktutan, U. (2009b) Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int. J. Stroke, 4, 461-470.
4. Allen, C., Srivastava, K. & Bayraktutan, U. (2010) Small GTPase RhoA and its effector rho kinase mediate oxygen glucose deprivation-evoked in vitro cerebral barrier dysfunction. Stroke, 41, 2056-2063.
5. Asahi, M., Asahi, K., Jung, J.C., del Zoppo, G.J., Fini, M.E. & Lo, E.H. (2000) Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cerebr. Blood F. Met., 20, 1681-1689.
6. Asahi, M., Sumii, T., Fini, M.E., Itohara, S. & Lo, E.H. (2001a) Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. NeuroReport, 12, 3003-3007.
7. Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J.C., Moskowitz, M.A., Fini, M.E. & Lo, E.H. (2001b) Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci., 21, 7724-7732.
8. Baramova, E.N., Bajou, K., Remacle, A., L'Hoir, C., Krell, H.W., Weidle, U.H., Noel, A. & Foidart, J.M. (1997) Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett., 405, 157-162.
9. Barr, T.L., Latour, L.L., Lee, K.Y., Schaewe, T.J., Luby, M., Chang, G.S., El-Zammar, Z., Alam, S., Hallenbeck, J.M., Kidwell, C.S. & Warach, S. (2010) Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke, 41, e123-e128.
10. Bayraktutan, U. (2004) Nitric oxide synthase and NAD(P)H oxidase modulate coronary endothelial cell growth. J. Mol. Cell. Cardiol., 36, 277-286.
11. Brouns, R. & De Deyn, P.P. (2009) The complexity of neurobiological processes in acute ischemic stroke. Clin. Neurol. Neurosur., 111, 483-495.
12. Cavdar, Z., Oktay, G., Egrilmez, M.Y., Genc, S., Genc, K., Altun, Z., Islekel, H. & Guner, G. (2010) In vitro reoxygenation following hypoxia increases MMP-2 and TIMP-2 secretion by human umbilical vein endothelial cells. Acta Biochim. Pol., 57, 69-73.
13. Chen, H., Song, Y.S. & Chan, P.H. (2009) Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion. J. Cerebr. Blood F. Met., 29, 1262-1272.
14. Chen, H., Kim, G.S., Okami, N., Narasimhan, P. & Chan, P.H. (2011) NADPH oxidase is involved in post-ischemic brain inflammation. Neurobiol. Dis., 42, 341-348.
15. Cho, E., Lee, K.J., Seo, J.W., Byun, C.J., Chung, S.J., Suh, D.C., Carmeliet, P., Koh, J.K., Kim, J.S. & Lee, J.Y. (2012) Neuroprotection by urokinase plasminogen activator in the hippocampus. Neurobiol. Dis., 46, 215-224.
16. Chrissobolis, S. & Faraci, F.M. (2008) The role of oxidative stress and NADPH oxidase in cerebrovascular disease. Trends Mol. Med., 14, 495-502.
17. Ear, T., Giguere, P., Fleury, A., Stankova, J., Payet, M.D. & Dupuis, G. (2001) High efficiency transient transfection of genes in human umbilical vein endothelial cells by electroporation. J. Immunol. Methods, 257, 41-49.
18. Eltzschig, H.K. & Collard, C.D. (2004) Vascular ischaemia and reperfusion injury. Brit. Med. Bull., 70, 71-86.
19. Fuhrman, B., Khateeb, J., Shiner, M., Nitzan, O., Karry, R., Volkova, N. & Aviram, M. (2008) Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism. Arterioscl. Throm. Vas., 28, 1361-1367.
20. Hacke, W., Donnan, G., Fieschi, C., Kaste, M., von Kummer, R., Broderick, J.P., Brott, T., Frankel, M., Grotta, J.C., Haley, E.C. Jr, Kwiatkowski, T., Levine, C., Lu, M., Lyden, P., Marler, J.R., Patel, S., Tilley, B.C., Albers, G., Bluhmki, E., Wilhelm, M. & Hamilton, S. (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet, 363, 768-774.
21. Haworth, R.S., Cragoe, E.J. Jr & Fliegel, L. (1993) Amiloride and 5-(N-ethyl-N-isopropyl) amiloride inhibit medium acidification and glucose metabolism by the fission yeast Schizosaccharomyces pombe. Biochim. Biophys. Acta, 1145, 266-272.
22. Hayashi, Y., Nomura, M., Yamagishi, S., Harada, S., Yamashita, J. & Yamamoto, H. (1997) Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia, 19, 13-26.
23. Hayashi, K., Nakao, S., Nakaoke, R., Nakagawa, S., Kitagawa, N. & Niwa, M. (2004) Effects of hypoxia on endothelial/pericytic co-culture model of the blood-brain barrier. Regul. Peptides, 123, 77-83.
24. Higazi, A.A., Mazar, A., Wang, J., Reilly, R., Henkin, J., Kniss, D. & Cines, D. (1996) Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood, 87, 3545-3549.
25. Hong, H., Zeng, J.S., Kreulen, D.L., Kaufman, D.I. & Chen, A.F. (2006) Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am. J. Physiol.-Heart C., 291, H2210-H2215.
26. Hosomi, N., Lucero, J., Heo, J.H., Koziol, J.A., Copeland, B.R. & del Zoppo, G.J. (2001) Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke, 32, 1341-1348.
27. Irigoyen, J.P., Munoz-Canoves, P., Montero, L., Koziczak, M. & Nagamine, Y. (1999) The plasminogen activator system: biology and regulation. Cell. Mol. Life Sci., 56, 104-132.
28. Kleikers, P.W., Wingler, K., Hermans, J.J., Diebold, I., Altenhofer, S., Radermacher, K.A., Janssen, B., Gorlach, A. & Schmidt, H.H. (2012) NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury. J. Mol. Med. (Berl), 90, 1391-1406.
29. Kleinschnitz, C., Grund, H., Wingler, K., Armitage, M.E., Jones, E., Mittal, M., Barit, D., Schwarz, T., Geis, C., Kraft, P., Barthel, K., Schuhmann, M.K., Herrmann, A.M., Meuth, S.G., Stoll, G., Meurer, S., Schrewe, A., Becker, L., Gailus-Durner, V., Fuchs, H., Klopstock, T., de Angelis, M., Jandeleit-Dahm, K., Shah, S.M., Weissmann, N. & Schmidt, H.H.H.W. (2010) Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol., 8, pii: e1000479.
30. Liu, J., Jin, X., Liu, K.J. & Liu, W. (2012) Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J. Neurosci., 32, 3044-3057.
31. Lucivero, V., Prontera, M., Mezzapesa, D.M., Petruzzellis, M., Sancilio, M., Tinelli, A., Di Noia, D., Ruggieri, M. & Federico, F. (2007) Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Neurol. Sci., 28, 165-170.
32. Margaill, I., Plotkine, M. & Lerouet, D. (2005) Antioxidant strategies in the treatment of stroke. Free Radical Biol. Med., 39, 429-443.
33. Nakase, T., Yoshioka, S. & Suzuki, A. (2011) Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke. BMC Neurol., 11, article 39.
34. Persidsky, Y., Ramirez, S.H., Haorah, J. & Kanmogne, G.D. (2006) Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharm., 1, 223-236.
35. Raat, N.J., Shiva, S. & Gladwin, M.T. (2009) Effects of nitrite on modulating ROS generation following ischemia and reperfusion. Adv. Drug Deliver. Rev., 61, 339-350.
36. Rosenberg, G.A., Dencoff, J.E., McGuire, P.G., Liotta, L.A. & Stetlerstevenson, W.G. (1994) Injury-induced 92-kilodalton gelatinase and urokinase expression in rat-brain. Lab. Invest., 71, 417-422.
37. Selemidis, S., Sobey, C.G., Wingler, K., Schmidt, H.H. & Drummond, G.R. (2008) NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol. Therapeut., 120, 254-291.
38. Shao, B. & Bayraktutan, U. (2013) Hyperglycaemia promotes cerebral barrier dysfunction through activation of protein kinase C-β. Diabetes Obes. Metab., 15, 993-999.
39. Shuaib, A., Lees, K.R., Lyden, P., Grotta, J., Davalos, A., Davis, S.M., Diener, H., Ashwood, T., Wasiewski, W.W. & Emeribe, U. (2007) NXY-059 for the treatment of acute ischemic stroke. New Engl. J. Med., 357, 562-571.
40. Suofu, Y., Clark, J.F., Broderick, J.P., Kurosawa, Y., Wagner, K.R. & Lu, A. (2012) Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion. Neuroscience, 212, 180-189.
41. Tahanian, E., Peiro, S. & Annabi, B. (2011) Low intracellular ATP levels exacerbate carcinogen-induced inflammatory stress response and inhibit in vitro tubulogenesis in human brain endothelial cells. J. Inflamm. Res., 4, 1-10.
42. Thornton, P., Pinteaux, E., Allan, S.M. & Rothwell, N.J. (2008) Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity. Mol. Cell. Neurosci., 37, 135-142.
43. Tsuji, K., Aoki, T., Tejima, E., Arai, K., Lee, S.R., Atochin, D.N., Huang, P.L., Wang, X., Montaner, J. & Lo, E.H. (2005) Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke, 36, 1954-1959.
44. Walder, C.E., Green, S.P., Darbonne, W.C., Mathias, J., Rae, J., Dinauer, M.C., Curnutte, J.T. & Thomas, G.R. (1997) Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. Stroke, 28, 2252-2258.
45. Wang, Z. & Kurpakus-Wheater, M. (2003) Decreased plasminogen activator inhibitor-1 secretion in hypoxic corneal epithelial cells is associated with increased urokinase plasminogen activator activity. Int. J. Biochem. Cell B., 35, 339-348.
46. Wang, Y.F., Tsirka, S.E., Strickland, S., Stieg, P.E., Soriano, S.G. & Lipton, S.A. (1998) Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med., 4, 228-231.